In CRC, CGP plays a crucial role in evaluating key biomarkers such as RAS, BRAF, HER2, MSI, TMB, RET fusions, and NTRK fusions, which are essential for selecting molecularly targeted therapies and ICIs. This evidence concerns the gene ERBB2 and colorectal carcinoma.